|
|
|
|
|
|
CHANGES OF LIFETIME MORPHOLOGICAL PARAMETERS OF THE RETINA ON THE BACKGROUND OF CORRECTION OF LIPID METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
N.N. Veselovskaya
Kyiv Medical University UAFM; Kyiv City Eye Center,
KCH №1.
DOI: https://doi.org/10.15407/fz63.01.091
Abstract
The functional changes of retina morphological parameters of
macular zone were investigated under condition of long term
action of fenofibrate, 145 mg in patients with diabetes mellitus
type 2. Dynamic observation of certain ophthalmologic
(visual acuity, macular thickness zone) and system functional
parameters (lipid fractions content in serum) in long-term use
of this medical drug in 20 patients with diabetes type 2 and
DMO for 8 months. In this period we revealed some positive
changes in the functional state of the macular area: increase of
visual acuity, decrease of macula thickness and the improvement
of the lipid profile in blood serum.
Keywords:
diabetes; macular edema; blood lipid fractions.
References
- Balashevich LI, Izmaylov AS, Brzheskiy VV. Ocular manifestations of diabetes. Saint Petersburg, MAPO, 2004; 123. [Russian].
- Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology. 1998; (105): 1801.
CrossRef
- Chaturvedi N, Sjolie AK., Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin Dependent Diabetes Mellitus. Lancet. 1998; (351): 28.
CrossRef
- UK Prospective Diabetes Study Group. UK Prospective Diabetes Study. XII: Differences between Asian, AfroCaribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabetes Medicine. 1994; (11): 670.
- Arbeneva NS, Patrina VV, Bratko GV, Chernykh VV, Sazonova OV. Experience of micronized fenofibrate in the proliferative diabetic retinopathy. Bulletin of the Novosibirsk State University. 2011; (4): 11‒14. [Russian].
- Veselovska NM. Risk factors for vascular pathology of eye in patients with diabetes. Clinical Endocrinology and Endocrine Surgery. 2013; (1): 42. [Ukrainian].
- Stephenson JM, Fuller JH, Viberti GC, Sjolie AK. Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study. Diabetologia. 1995; (38): 599.
CrossRef
PubMed
- Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991; (98): 1261.
CrossRef
- Early Treatment Diabetes Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmology. 1991; (98): 1262.
- Keating GM, Croom KF. Fenofibrate. A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes mellitus. Drugs. 2007; (67): 121.
CrossRef
PubMed
- Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes; The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001; (357): 905.
PubMed
- Wright AD, Dodson PM. Medical management of diabetic retinopathy fenofibrate and ACCORD Eye studies. Eye. 2011; (25): 843.
CrossRef
PubMed PubMedCentral
- Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007; (370): 1687.
CrossRef
|
|
|
|
|
|
|
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.
|
|